338
Views
9
CrossRef citations to date
0
Altmetric
Articles

Altered serum levels of vascular endothelial growth factor and glial-derived neurotrophic factor but not fibroblast growth factor-2 in treatment-naive children with attention deficit/hyperactivity disorder

ORCID Icon, & ORCID Icon
Pages 302-307 | Received 30 Jan 2019, Accepted 27 May 2019, Published online: 07 Jun 2019

References

  • Polanczyk G, Salum GA, Sugaya LS. Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry. 2015;56:345–365.
  • Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21:655–679.
  • Willcutt EG. The prevalence of DSM-IV attention-deficit/hyperactivity disorder: a meta-analytic review. Neurotherapeutics. 2012;9:490–499.
  • Schuch V, Utsumi DA, Costa TV, et al. Attention deficit hyperactivity disorder in the light of the epigenetic paradigm. Front Psychiatry. 2015;6:126.
  • Galvez-Contreras AY, Campos-Ordonez T, Gonzalez-Castaneda RE, et al. Alterations of growth factors in autism and attention-deficit/hyperactivity disorder. Front Psychiatry. 2017;8:126.
  • Galvez-Contreras AY, Campos-Ordonez T, Lopez-Virgen V, et al. Growth factors as clinical biomarkers of prognosis and diagnosis in psychiatric disorders. Cytokine Growth Factor Rev. 2016;32:85–96.
  • Bibel M, Barde YA. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev. 2000;14:2919–2937.
  • Thoenen H. Neurotrophins and activity-dependent plasticity. Prog Brain Res. 2000;128:183–191.
  • Lewin GR, Barde YA. Physiology of the neurotrophins. Annu Rev Neurosci. 1996;19:289–317.
  • Naumenko VS, Bazovkina DV, Semenova AA, et al. Effect of glial cell line-derived neurotrophic factor on behavior and key members of the brain serotonin system in mouse strains genetically predisposed to behavioral disorders. J Neurosci Res. 2013;91:1628–1638.
  • Bilgiç A, Toker A, Işık Ü, et al. Serum brain-derived neurotrophic factor, glial-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 levels in children with attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2017;26:355–363.
  • Tunca Z, Kıvırcık Akdede B, Özerdem A, et al. Diverse glial cell line-derived neurotrophic factor (GDNF) support between mania and schizophrenia: a comparative study in four major psychiatric disorders. Eur Psychiatry. 2015;30:198–204.
  • Sharma AN, da Costa e Silva BF, Soares JC, et al. Role of trophic factors GDNF, IGF-1 and VEGF in major depressive disorder: a comprehensive review of human studies. J Affect Disord. 2016;197:9–20.
  • Pallavi P, Sagar R, Mehta M, et al. Serum neurotrophic factors in adolescent depression: gender difference and correlation with clinical severity. J Affect Disord. 2013;150:415–423.
  • Shim SH, Hwangbo Y, Yoon HJ, et al. Increased levels of plasma glial-derived neurotrophic factor in children with attention deficit hyperactivity disorder. Nord J Psychiatry. 2015;69:546–551.
  • Maness LM, Kastin AJ, Weber JT, et al. The neurotrophins and their receptors: structure, function, and neuropathology. Neurosci Biobehav Rev. 1994;18:143–159.
  • Ribases M, Hervas A, Ramos-Quiroga JA, et al. Association study of 10 genes encoding neurotrophic factors and their receptors in adult and child attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63:935–945.
  • Connor B, Dragunow M. The role of neuronal growth factors in neurodegen erative disorders of the human brain. Brain Res Rev. 1998;27:1–39.
  • Rylett RJ, Williams LR. Role of neurotrophins in cholinergic-neurone function in the adult and aged CNS. Trends Neurosci. 1994;17:486–490.
  • Guney E, Ceylan MF, Kara M, et al. Serum nerve growth factor (NGF) levels in children with attention deficit/hyperactivity disorder (ADHD). Neurosci Lett. 2014;560:107–111.
  • Beck L, D'Amore PA. Vascular development: cellular and molecular regulation. Faseb J. 1997;11:365–373.
  • Bikfalvi A, Klein S, Pintucci G, et al. Biological roles of fibroblast growth factor-2. Endocr Rev. 1997;18:26–45.
  • Mooney MA, McWeeney SK, Faraone SV, et al. Pathway analysis in attention deficit hyperactivity disorder: an ensemble approach. Am J Med Genet B Neuropsychiatr Genet. 2016;171:815–826.
  • Virgintino D, Errede M, Robertson D, et al. VEGF expression is developmentally regulated during human brain angiogenesis. Histochem Cell Biol. 2003;119:227–232.
  • Jesmin S, Togashi H, Mowa CN, et al. Characterization of regional cerebral blood flow and expression of angiogenic growth factors in the frontal cortex of juvenile male SHRSP and SHR. Brain Res. 2004;1030:172–182.
  • Jesmin S, Togashi H, Sakuma I, et al. Gonadal hormones and frontocortical expression of vascular endothelial growth factor in male stroke-prone, spontaneously hypertensive rats, a model for attention-deficit/hyperactivity disorder. Endocrinology. 2004;145:4330–4343.
  • Oakes HV, DeVee CE, Farmer B, et al. Neurogenesis within the hippocampus after chronic methylphenidate exposure. J Neural Transm. 2019;126(2):201–209.
  • Emanuele E, Orsi P, Barale F, et al. Serum levels of vascular endothelial growth factor and its receptors in patients with severe autism. Clin Biochem. 2010;43:317–319.
  • Masi A, Breen EJ, Alvares GA, et al. Cytokine levels and associations with symptom severity in male and female children with autism spectrum disorder. Mol Autism. 2017;8:63.
  • Kaufman J, Birmaher B, Brent D, et al. Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980–988.
  • Gökler B, Ünal F, Pehlivantürk B, et al. The reliability and validity of the Turkish version of schedule for affective disorders and schizophrenia – present and lifetime version for school children. Turk J Child Adolesc Ment Health. 2004;11:109–116.
  • Dupaul G, Anastopoulos A, Power T, et al. ADHD rating scale IV: checklists, norms and clinical interpretation. New York (NY): Guilford Press; 1998.
  • Pekcanlar A, Turgay A, Miral S, et al. Attention deficit hyperactivity disorder and family functions. Turk J Child Adolesc Ment Health. 1999;6:99–107.
  • Akay AP, Resmi H, Güney SA, et al. Serum brain-derived neurotrophic factor levels in treatment-naïve boys with attention-deficit/hyperactivity disorder treated with methylphenidate: an 8-week, observational pretest-posttest study. Eur Child Adolesc Psychiatry. 2018;27:127–135.
  • Goodman R. The strengths and difficulties questionnaire: a research note. J Child Psychol Psychiat. 1997;38:581–586.
  • Güvenir T, Özbek A, Baykara B, et al. Psychometric properties of the Turkish Version of The Strengths and Difficulties Questionnaire (SDQ). Turk J Child Adolesc Ment Health. 2008;15:65–74.
  • Zhang J, Luo W, Li Q, et al. Peripheral brain-derived neurotrophic factor in attention-deficit/hyperactivity disorder: a comprehensive systematic review and meta-analysis. J Affect Disord. 2018;227:298–304.
  • Amiri A, Torabi Parizi G, Kousha M, et al. Changes in plasma brain-derived neurotrophic factor (BDNF) levels induced by methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD). Prog Neuropsychopharmacol Biol Psychiatry. 2013;47:20–24.
  • Sahin S, Yuce M, Alacam H, et al. Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain-derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder. Int J Psychiatry Clin Pract. 2014;18:280–287.
  • Conner AC, Kissling C, Hodges E, et al. Neurotrophic factor-related gene polymorphisms and adult attention deficit hyperactivity disorder (ADHD) score in a high-risk male population. Am J Med Genet B Genet. 2008;147:1476–1480.
  • Cho SC, Kim HW, Kim BN, et al. Neurotrophin-3 gene, intelligence, and selective attention deficit in a Korean sample with attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:1065–1069.
  • He S, Zhang T, Hong B, et al. Decreased serum fibroblast growth factor - 2 levels in pre- and post-treatment patients with major depressive disorder. Neurosci Lett. 2014;579:168–172.
  • Turner CA, Watson SJ, Akil H. The fibroblast growth factor family: neuromodulation of affective behavior. Neuron. 2012;76:160–174.
  • Smith KM, Fagel DM, Stevens HE, et al. Deficiency in inhibitory cortical interneurons associates with hyperactivity in fibroblast growth factor receptor 1 mutant mice. Biol Psychiatry. 2008;63:953–962.
  • Cao L, Jiao X, Zuzga DS, et al. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet. 2004;36:827–835.
  • Fumagalli F, Cattaneo A, Caffino L, et al. Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: comparison with methylphenidate. Pharmacol Res. 2010;62:523–529.
  • Kirby ED, Kuwahara AA, Messer RL, et al. Adult hippocampal neural stem and progenitor cells regulate the neurogenic niche by secreting VEGF. Proc Natl Acad Sci USA. 2015;112:4128–4133.
  • Lee TH, Lee CH, Kim IH, et al. Effects of ADHD therapeutic agents, methylphenidate and atomoxetine, on hippocampal neurogenesis in the adolescent mouse dentate gyrus. Neurosci Lett. 2012;524:84–88.
  • Warner-Schmidt JL, Duman RS. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus. 2006;16:239–249.
  • Warner-Schmidt JL, Duman RS. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA. 2007; 104:4647–4652.
  • Allred EN, Dammann O, Fichorova RN, ELGAN Study ADHD symptoms writing group for, et al. The ELGAN Study Investigators. Systemic inflammation during the first postnatal month and the risk of attention deficit hyperactivity disorder characteristics among 10 year-old children born extremely preterm. J Neuroimmune Pharmacol. 2017;12:531–543.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.